589 related articles for article (PubMed ID: 25054392)
1. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
[TBL] [Abstract][Full Text] [Related]
2. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
[TBL] [Abstract][Full Text] [Related]
3. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain.
Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Dogan C; Etropolski M; Eerdekens M
Eur J Pain; 2016 Oct; 20(9):1513-8. PubMed ID: 27062079
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
[TBL] [Abstract][Full Text] [Related]
5. A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain.
Etropolski M; Lange B; Goldberg J; Steup A; Rauschkolb C
J Opioid Manag; 2013; 9(5):343-56. PubMed ID: 24353047
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.
Schwartz S; Etropolski M; Shapiro DY; Okamoto A; Lange R; Haeussler J; Rauschkolb C
Curr Med Res Opin; 2011 Jan; 27(1):151-62. PubMed ID: 21162697
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
Buynak R; Shapiro DY; Okamoto A; Van Hove I; Rauschkolb C; Steup A; Lange B; Lange C; Etropolski M
Expert Opin Pharmacother; 2010 Aug; 11(11):1787-804. PubMed ID: 20578811
[TBL] [Abstract][Full Text] [Related]
8. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.
Biondi DM; Xiang J; Etropolski M; Moskovitz B
J Opioid Manag; 2015; 11(5):393-403. PubMed ID: 26535967
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
Afilalo M; Morlion B
Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
[TBL] [Abstract][Full Text] [Related]
10. Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study.
Serrie A; Lange B; Steup A
Curr Med Res Opin; 2017 Aug; 33(8):1423-1432. PubMed ID: 28537501
[TBL] [Abstract][Full Text] [Related]
11. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
Biondi D; Xiang J; Benson C; Etropolski M; Moskovitz B; Rauschkolb C
Pain Physician; 2013; 16(3):E237-46. PubMed ID: 23703422
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies.
Lange B; von Zabern D; Elling C; Dubois C
Curr Med Res Opin; 2017 Aug; 33(8):1413-1422. PubMed ID: 28537506
[TBL] [Abstract][Full Text] [Related]
13. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy.
Vinik AI; Shapiro DY; Rauschkolb C; Lange B; Karcher K; Pennett D; Etropolski MS
Diabetes Care; 2014 Aug; 37(8):2302-9. PubMed ID: 24848284
[TBL] [Abstract][Full Text] [Related]
14. Dose conversion between tapentadol immediate and extended release for low back pain.
Etropolski MS; Okamoto A; Shapiro DY; Rauschkolb C
Pain Physician; 2010; 13(1):61-70. PubMed ID: 20119464
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.
Steigerwald I; Schenk M; Lahne U; Gebuhr P; Falke D; Hoggart B
Clin Drug Investig; 2013 Sep; 33(9):607-19. PubMed ID: 23912473
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials.
Etropolski M; Kuperwasser B; Flügel M; Häufel T; Lange B; Rauschkolb C; Laschewski F
Adv Ther; 2014 Jun; 31(6):604-20. PubMed ID: 24985410
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
Afilalo M; Etropolski MS; Kuperwasser B; Kelly K; Okamoto A; Van Hove I; Steup A; Lange B; Rauschkolb C; Haeussler J
Clin Drug Investig; 2010; 30(8):489-505. PubMed ID: 20586515
[TBL] [Abstract][Full Text] [Related]
19. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
[TBL] [Abstract][Full Text] [Related]
20. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
Peniston JH; Gould E
Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
